Data from a pooled post hoc analysis of 14 placebo-controlled, dapagliflozin treatment studies in patients with type 2 diabetes with and without anemia at baseline

Data from a pooled post hoc analysis of 14 placebo-controlled, dapagliflozin treatment studies in patients with type 2 diabetes with and without anemia at baseline

Dapagliflozin is a highly selective sodium-glucose cotransporter 2 inhibitor associated with stabilization of estimated glomerular filtration rate (eGFR); reductions in glycated hemoglobin (HbA1c), systolic blood pressure, body weight, and albuminuria; and a small and consistent increase in hematocr...

Full description

Bibliographic Details
Main Authors: Bergur V. Stefánsson, Hiddo J.L. Heerspink, David C. Wheeler, C. David Sjöström, Peter J. Greasley, Peter Sartipy, Valerie Cain, Ricardo Correa-Rotter
Format: Article
Language:English
Published: Elsevier 2021-08-01
Series:Data in Brief
Subjects:
Anemia
Chronic kidney disease
Dapagliflozin
eGFR
Hematocrit
Hemoglobin
Online Access:http://www.sciencedirect.com/science/article/pii/S2352340921005217

Internet

http://www.sciencedirect.com/science/article/pii/S2352340921005217

Similar Items